Minerva Imaging
CRO/CDMO for targeted radionuclide therapy drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Growth Equity VC | |
| Total Funding | 000k | ||
| DKK | 2023 | 2024 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Minerva Imaging is a Contract Research Organisation (CRO) and a Contract Development and Manufacturing Organisation (CDMO) founded in 2011. The company spun out from the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark, building on over two decades of research. Its founders are Andreas Kjaer, who serves as Chairman of the Board, and Carsten Haagen Nielsen, the company's CEO.
The company operates as a scientifically-driven partner for pharmaceutical and biotech companies, specializing in targeted radionuclide therapies for translational research and drug development. Minerva Imaging provides an integrated service platform that covers the entire development process from preclinical research to clinical cGMP (Good Manufacturing Practice) supplies for first-in-human studies and beyond. Its core focus areas are oncology and cardiovascular diseases, utilizing advanced in-vivo disease models and molecular imaging technologies such as PET, SPECT, CT, and MRI to support drug development programs. The business model is service-based, generating revenue by offering these specialized research, development, and manufacturing services to a global client base. In 2024, the company generated revenue of more than DKK 225 million.
In June 2025, Minerva Imaging entered into a strategic partnership with Nordic Capital, a private equity investor, to accelerate its growth and global expansion. The transaction, expected to close in the third quarter of 2025, will see Nordic Capital co-own the company alongside the founders. This partnership aims to enhance Minerva's service offerings and solidify its position in the rapidly growing radiopharmaceuticals market. The company is headquartered in Ølstykke, Denmark, and employs over 150 people.
Keywords: radiopharmaceuticals, radionuclide therapy, CRO, CDMO, molecular imaging, preclinical oncology, translational research, drug development, GMP manufacturing, theranostics, in-vivo models, cardiovascular disease models, PET imaging, SPECT imaging, radioligand therapy, drug discovery, biopharmaceutical services, cGMP services, clinical trials support, pharmaceutical diagnostics